Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Finished Drug Prices
NA
1. (1s)-1,5-anhydro-1-(3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl)-d-glucitol
2. Asp-1941
3. Asp1941
4. Suglat
1. 761423-87-4
2. Suglat
3. Asp-1941
4. Asp1941
5. Ipragliflozin [inn]
6. (2s,3r,4r,5s,6r)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
7. Ipragliflozin (asp1941)
8. 3n2n8oor7x
9. Chembl2018096
10. (1s)-1,5-anhydro-1-c-[3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl]-d-glucitol
11. Ipragliflozin (inn)
12. (1s)-1,5-anhydro-1-c-(3-((1-benzothiophen-2-yl)methyl)-4-fluorophenyl)-d-glucitol
13. Asp 1941
14. Unii-3n2n8oor7x
15. Ipragliflozin-l-proline
16. Ipragliflozin [mi]
17. (2s,3r,4r,5s,6r)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
18. Schembl337645
19. Ipragliflozin [who-dd]
20. Gtpl9394
21. Chebi:134724
22. Dtxsid701032738
23. Amy38779
24. Ex-a2770
25. Bdbm50381554
26. Mfcd19443744
27. S8637
28. Zinc38897728
29. Akos025405258
30. Ccg-268693
31. Db11698
32. Ncgc00378606-02
33. Ac-29008
34. As-39358
35. Hy-14894
36. D10196
37. Q17193526
38. (1s)-1,5-anhydro-1-(3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl)-d-glucitol
39. (1s)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-d-glucitol
40. (1s)-1,5-anhydro-1-c-[3-(1-benzothiophene-2-ylmethyl)-4-fluorophenyl]-d-glucitol
41. D-glucitol,1,5-anhydro-1-c-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1s)-
42. (2s,3r,4r,5s,6r)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
43. D-glucitol, 1,5-anhydro-1-c-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-, (1s)-
Molecular Weight | 404.5 g/mol |
---|---|
Molecular Formula | C21H21FO5S |
XLogP3 | 2.5 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 4 |
Exact Mass | 404.10937310 g/mol |
Monoisotopic Mass | 404.10937310 g/mol |
Topological Polar Surface Area | 118 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 525 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Sodium-Glucose Transporter 2 Inhibitors
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
A10BK05 - Ipragliflozin
Global Sales Information
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?